Shield Therapeutics - 2019 a landmark year
Today’s 2019 business and trading update highlights a landmark year for Shield Therapeutics. Feraccru/Accrufer (oral ferric maltol) is making...
799 Views
Shield Therapeutics - Feraccru out-licensed in China
Shield Therapeutics has kick-started 2020 by securing an out-licensing deal in China for its primary asset, Feraccru/Accrufer. The exclusive deal...
971 Views